Physician profile
Rachel Lynn Blasingame
NPI 1326791005
$695.14
in general payments reported to CMS, 2019-2025
12 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $119 · 2023: $238 · 2024: $215 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $183.69 | 2023-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $114.26 | 2022-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $90.85 | 2023-2025 | |
| Novo Nordisk INC | $69.56 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $44.53 | 2023 | Verquvo |
| Abbvie INC. | $34.21 | 2023 | |
| Boston Scientific Corporation | $34.01 | 2024 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $33.37 | 2022-2025 | Airsupra |
| Madrigal Pharmaceuticals | $27.32 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $22.06 | 2025 | Cologuard Collection Kit |
| Philips North America LLC | $20.76 | 2023 | |
| Amgen INC. | $20.52 | 2024 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Blasingame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.